What is one of the contraindications for administering Bevacizumab?

Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), which is vital for tumor angiogenesis. One of the key contraindications for administering Bevacizumab is the timing of the treatment concerning surgical interventions. Administering Bevacizumab within 28 days before surgery can lead to complications such as impaired wound healing and increased risk of postoperative bleeding. This is due to its ongoing effects on blood vessel formation and maintenance, which can affect recovery and healing processes after surgical procedures.

In contrast, factors like blood pressure over 140/90, while important to monitor, are not absolute contraindications for Bevacizumab therapy. Active infections can complicate treatment but do not serve as a strict contraindication; instead, the clinical team would evaluate the overall patient status carefully. Severe fatigue is also not a contraindication but rather a potential side effect of cancer treatment that may require management. Understanding these aspects is crucial for the safe administration of Bevacizumab in cancer treatment.